Takeda Pharmaceutical Co Stock (NYSE: TAK)

Dernières nouvelles pour Takeda Pharmaceutical Co (NYSE:TAK) Stock

Takeda Pharmaceutical Co

Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co Ltd

TransAKT Ltd

TAKIGAMI STEEL CONSTRCTN by Takigami Steel Construction Co. Ltd.

Takigami Steel Construction Co Ltd

TAKAMATSU CONSTRUCTION GR by TAKAMATSU CONSTRUCTION GROUP CO LTD

Takamatsu Construction Group Co Ltd

VOLATUS AEROSPACE INC by VOLATUS AEROSPACE INC.

Volatus Aerospace Inc

TAKEDA PHARMA  ADR REP 0.5 ORD

News

ONCT

Oncternal Therapeutics Announced Workforce Reduction Effective December 2, 2024; Four Employees Will Remain In A Part-time Capacity In Connection With Exploration Of Strategic Alternatives; Expects $2.4M In Charges From Workforce Reduction

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Trading Ideas

Third Point 13F Shows Increased Stake In Intercontinental Exchange By 109% From 1,000,000 To 2,085,000 Shares; Live Nation Entertainment By 71% From 1,365,000 To 2,340,000 Shares; CRH By 215% From 650,000 To 2,050,000 Shares; Telephone & Data Systems By 27% From 2,266,060 To 2,875,000 Shares

Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.87) by 3.45 percent.

Earnings

Earnings Beats

Kodiak Sciences Q3 2024 GAAP EPS $(0.84) Beats $(0.87) Estimate

Offerings

Associated Banc-Corp Announces Proposed Common Stock Offering Of 11.5M Shares

ANSS

FERG

FLUT

LPLA

TSLA

Third Point 13F Shows Added Stake In Brookfield Corp With 4,725,000 Shares; Ferguson Enterprises With 965,000 Shares; Flutter Entertainment With 510,000 Shares; LPL Financial Holdings With 485,000 Shares; Carpenter Technology With 660,000 Shares; Tesla With 400,000 Shares; CVS Health Corp With 1,575,000 Shares; Ansys With 255,000 Shares; Hawaiian Electric Industries With 1,535,000 Shares; Clear Channel Outdoor Holdings With 850,000 Shares

ABVX

Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY

Events

ASTS

AST SpaceMobile Announced It Has Made Significant Strides Its Mission To Establish the First Space-Based Cellular Broadband Network

Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)&#8217;s chief financial officer and two other insiders have sold millions of dollars worth of shares following the election, <a href="https://www.benzinga.com/quote/DJT">according to SEC filings</a>. 
The Details: Trump Media's CFO and treasurer Phillip Juhan sold 320,000 shares on Friday, Nov. 8 at a price of $30.65 per share for a total of $9.8 million in stock, according to a Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000239/xslF345X05/primary_doc.xml">filing.</a> On Monday, Juhan sold another 64,000 shares at $32.97 per share, or $2.11 million in stock, according to the same filing.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
Juhan previously <a href="https://www.sec.gov/Archives/edgar/data/1849635/000114036124045278/ef20038154_424b3.htm">disclosed </a>a trading plan that revealed his intention to sell 400,000 Trump Media &amp; Technology shares by December 2025. Juhan still holds 265,798 shares of DJT, according to the filing, most of which are restricted stock units (RSUs) <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000234/xslF345X05/primary_doc.xml">awarded </a>to him on Nov. 5 that cannot be immediately sold.
One-quarter of Juhan's restricted stock units will become eligible for sale on Dec. 25, 2024, and the remaining shares will vest in quarterly installments through March 2027.
Scott Glabe, Trump Media's general counsel and secretary, on Friday sold 15,917 shares for $32.19 per share, or a total of $512,368, an SEC <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000240/xslF345X05/primary_doc.xml">filing </a>shows.&nbsp; Glabe still <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000236/xslF345X05/primary_doc.xml">holds</a> 336,576 restricted stock units in Trump Media which will vest according to the same schedule as Juhan's RSUs.
Eric Swider, director, sold 136,183 shares of DJT on Friday at $28.23 per share, or a total of $3.84 million in stock, according to his Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000238/xslF345X05/primary_doc.xml">filing</a>. Swider disposed of all of his shares, but his company, Renatus Advisors, still owns 18,043 shares of Trump Media.
Benzinga reached out to Trump Media &amp; Technology Group for comment on the stock sales.
Donald Trump, the majority shareholder of Trump Media &amp; Technology, <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000146/xslF345X05/primary_doc.xml">holds</a> 114.75 million shares, representing about 60% of the company&#8217;s total shares. Trump <a href="https://www.benzinga.com/media/24/11/41853221/trump-says-he-wont-sell-trump-media-stock">denied rumors </a>of a potential share sale in a post on Truth Social last Thursday.&nbsp;
Trump said the rumors were &#8220;fake, untrue, and probably illegal,&#8221; likely spread by market manipulators or short sellers. He emphasized, &#8220;I have no intention of selling.&#8221;
DJT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology shares were down 3.84% at $27.82 late in Thursday&#8217;s trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock.

Social Media

Politics

Insider Trades

Movers

Trump Media Insiders Sell More Than $16 Million In DJT Stock

Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $953.00 thousand which missed the analyst consensus estimate of $1.25 million by 23.76 percent. This is a 30.89 percent decrease over sales of $1.38 million the same period last year.

Earnings Misses

PGEN

Precigen Q3 2024 GAAP EPS $(0.09) Misses $(0.08) Estimate, Sales $953.00K Miss $1.25M Estimate

Billionaire Elon Musk may have been one of the central figures in the 2024 presidential election and Republican voters now view him more favorably than a year ago after Donald Trump <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">won the election.</a>
What Happened: Musk endorsed Trump in the 2024 presidential election and<a href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther"> campaigned for the president-elect </a>in the key swing state of Pennsylvania.
Since helping Trump win the 2024 election, Musk has been <a href="https://www.benzinga.com/government/regulations/24/11/41931503/trump-forms-doge-with-elon-musk-and-vivek-ramaswamy-at-the-helm-will-it-impact-tesla-ceos-role-at-the-ev-giant-and-spacex">named to lead</a> the Department of Government Efficiency, or D.O.G.E for short, alongside Vivek Ramaswamy.
Musk will likely play a central role in the Trump administration going forward and it comes as Republicans have a more favorable opinion of the billionaire.
A Morning Consult <a href="https://pro.morningconsult.com/analysis/elon-musk-trump-administration-influence">poll </a>conducted on Nov. 6 and Nov. 7 after Trump won the election found that 72% of Republicans had a favorable view of Musk, up from 52% a year ago. The poll found that 17% of Republican had an unfavorable view of Musk. The remaining respondents said they had heard of Musk and had no opinion (10%) or had never heard of Musk (1%).
For comparison, here is how Musk's favorable and unfavorable ratings compare to other key Republican figures. The following are the percent of Republican voters who said they viewed each person favorable or unfavorable:
<ul>
<li>Donald Trump: 87% favorable, 11% unfavorable</li>
<li>Republicans in Congress: 83% favorable, 12% unfavorable</li>
<li>J.D. Vance: 74% favorable, 12% unfavorable</li>
<li>Mike Johnson: 39% favorable, 14% unfavorable</li>
<li>Mitch McConnell: 29% favorable, 37% unfavorable</li>
</ul>
The poll shows Musk's favorable rating ranking nearly the same as vice-president-elect Vance. Musk also is viewed more favorable by Republicans than that of Speaker of the House Johnson and current Senate Minority Leader McConnell.
Musk does have the second worst unfavorable rating at 17%, ranking only ahead of McConnell, who has often clashed with Trump and members of his own party.
The poll also found that 53% of Republicans said Musk should play "a major role" in the Trump administration moving forward. This ranked ahead of Robert F. Kennedy Jr., who saw 49% of Republican voters say he should play a major role moving forward.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk is viewed much more favorably by Republican voters than Democrats and Independent voters according to the latest poll.
The poll found that Democratic voters view Musk more unfavorable (71%) than favorable (17%). This is a big change from a year ago when Musk had a favorable rating of 32% and unfavorable rating of 46% from Democratic voters.
Independent voters are also more likely to have an unfavorable view of Musk (48%) than a favorable one (36%). This is a change from a year ago when 40% had unfavorable views of Musk and 34% viewed him favorable.
Overall, Musk had a favorable rating of 42% and unfavorable rating of 45% across all voters, compared to 40% favorable and 36% unfavorable a year ago.
Morning Consult has conducted the poll asking for views on Musk four times based on the latest poll, with results coming for April 2022, June 2022, November 2023 and November 2024.
Musk had his highest overall favorable rating of 45% from all voters back in April 2022.
While Musk's favorable rating is up to 72% and his unfavorable rating was down compared to a year ago amongst Republican voters, Musk had a lower unfavorable rating from Republican voters of 13% back in April 2022.
One of the key questions moving forward is if Musk's support of Trump, who has been a vocal critic of electric vehicles will hurt Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Based on the surging price of Tesla stock since the 2024 election, Tesla investors see a Trump win as a positive with shares up 14.8% on the day after the election. Tesla stock is up 24.6% since the closing price on Election Day.
Trump's win could see the end of federal credits for electric vehicles, which could be negative for the sector. Tesla may not lose as much as the company is profitable and has large scale compared to electric vehicle competitors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41887136/snl-parodies-elon-musk-and-donald-trump-after-2024-election-billionaire-says-show-is-out-of-touch-with-reality">SNL Parodies Elon Musk And Donald Trump After 2024 Election: Billionaire Says Show Is &#8216;Out Of Touch With Reality&#8217;</a></li>
</ul>
Image: Shutterstock

Elon Musk's Favorability With GOP Voters Nearly As High As J.D. Vance: How Views Of Billionaire Changed Among Political Parties

Chardan Capital analyst Keay Nakae downgrades Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) from Buy to Neutral.

Downgrades

ALUR

Chardan Capital Downgrades Allurion Technologies to Neutral

Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.35) by 66.67 percent. The company reported quarterly sales of $328.400 million which beat the analyst consensus estimate of $16.400 million by 1.90K percent. This is a 60.35 percent increase over sales of $204.800 million the same period last year.

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Hldgs Q3 2024 GAAP EPS $(0.45) Beats $(1.35) Estimate, Sales $328.400M Beat $16.400M Estimate

Financing

XCUR

Exicure Enters Into Purchase Agreements For $1.3M And $8.7M Equity Financing

Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.67) by 76.05 percent. The company reported quarterly sales of $5.863 million which missed the analyst consensus estimate of $6.000 million by 2.28 percent. This is a 218.30 percent increase over sales of $1.842 million the same period last year.

SYTA

Siyata Mobile Q3 2024 GAAP EPS $(0.40) Beats $(1.67) Estimate, Sales $5.863M Miss $6.000M Estimate

Exicure Q3 EPS $(0.57) Up From $(3.04) YoY

WIIM

ADGM

Adiago Medical Holdings shares are trading after the company reported better-than-expected Q3 financial results.

Contracts

AXON

Axon Wins Federal Government Contract To Supply Royal Canadian Mounted Police With Body-Worn Cameras; Terms Not Disclosed

Outlook
Post management expects Adjusted EBITDA for fiscal year 2025 to be between $1,410-$1,460 million. Post management expects fiscal year 2025 capital expenditures to range between $380-$420 million, which includes Post Consumer Brands investment in network optimization and pet food safety and capacity, for aggregate expenditures of $90-$100 million. This also includes Foodservice investment in the completion of the Norwalk, Iowa precooked egg facility expansion and continued cage-free egg facility expansion, for aggregate expenditures of $80-$90 million.
Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for income/expense on swaps, net, gain/loss on extinguishment of debt, net, integration and transaction costs, mark-to-market adjustments on commodity and foreign exchange hedges, mark-to-market adjustments and impairments on equity securities and investments, equity method investment adjustment and other charges reflected in Post's reconciliations of historical numbers, the amounts of which, based on historical experience, could be significant. For additional information regarding Post's non-GAAP measures, see the related explanations presented under "Use of Non-GAAP Measures."

Guidance

POST

Post Management Expects Adjusted EBITDA For FY25 To Be Between $1.410B-$1.460B; Capital Expenditures To Range Between $380M-$420M

BRLS

Borealis Foods Q3 EPS $(0.23) Up From $(0.61) YoY, Net Revenue $7.69M Down From $7.72M YoY

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Takeda Pharmaceutical FQ2 Earnings Preview

Takeda Pharmaceutical reports H1 results, revises FY forecast

Takeda Pharmaceutical Company Limited 2025 Q2 - Results - Earnings Call Presentation

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Takeda Pharmaceutical Company ( ($TAK) ) has released its Q2 earnings. Here is a breakdown of the information Takeda Pharmaceutical Company present...

Takeda Pharmaceutical Announces Robust Earnings Growth

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX – Research Report), Taked...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Takeda Pharmaceutical Company (TAK) and Voyager Therapeutics (VYGR)

Alkermes raised to buy by Stifel on increased confidence for ALKS2680

Trump victory is a win for Japan equities, a loss for China – analyst

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

ALKS

ALPMY

APELY

APLS

BCRX

CRBP

DERM

ELAB

FLAU

FLIN

FUJIY

INDA

MCHI

NKTR

NTLA

OMRNY

REGN

RPRX

STBFY

TKPHF

TTDKY

TVTX

VKTX

VRCA

VRNA

VYGR

Press Releases

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

Comments

Takeda Pharmaceutical Co

Actualités

Dernières nouvelles pour Takeda Pharmaceutical Co (NYSE:TAK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL